What experiments gave · 05
What can TB-500 dosage studies tell a patient?
The copy studied for healing has no established patient treatment amount. This page describes animal experiments and human testing of the larger protein. Plans from people experimenting on themselves haven't been checked in controlled trials.
Which TB-500 dosage claims come from tests of another substance?
TB-500 dosage claims often rely on experiments that used whole thymosin beta-4. Stroke studies gave rats shots into the space around belly organs, with no steady rise in benefit as amounts increased [4]. Mice with muscle disease received 150 micrograms twice weekly for 6 months; micrograms are tiny millionths of a gram [5]. The mice also received belly-space injections; their study amounts cannot set an amount for human treatment.
Skin cells moved more in a dish with 10 picograms, a speck too light for a kitchen scale [3][5]. Cells surrounding hair roots became active with tiny amounts of thymosin beta-4 too. A dish experiment cannot show which amount would help your injury. The tested substance matters too, since the copy and the larger protein differ.
The human Phase 1 safety study gave whole thymosin beta-4 through a vein [6]. Groups were assigned 42, 140, 420 or 1260 milligrams, units equal to thousandths of a gram. The first part tested a single injection; a later part tested daily injections for 14 days. These were parts of the larger-protein study carried out one after another, rather than an established course for your use of the copy.
Other experiments put treatment on skin or eyes, while the Phase 1 safety study used a vein [12]. People using research products on themselves describe larger starting amounts followed by smaller amounts [12]. The plans lack a controlled human test of safety or improved healing. Your treatment question therefore cannot be answered by copying an animal experiment or another person's plan.
Did larger study amounts help the rats more after stroke?
Researchers caused stroke in rats by blocking a brain artery, then gave thymosin beta-4 [4]. Each kilogram means just over two pounds of body weight; injections entered the space around the belly organs. At 2 and 12 milligrams per kilogram, rats regained better control of movement from day 14 through day 56. The 18 milligrams per kilogram amount brought no clear benefit.
The highest amount wasn't the most helpful, which matters when judging claims about your recovery. People experimenting on themselves describe larger starting amounts, without human trials supporting that approach [12]. The rat study establishes neither a treatment amount nor a plan for your recovery. Raising or lowering an animal amount cannot supply evidence about safe treatment for people.
Recovery after stroke improved in rats given 12 milligrams per kilogram, while the 18 milligrams per kilogram amount did not clearly help [4]. Body weight determined both amounts, and the substance used was the whole protein. Those results don't show pain relief, muscle strength, or human treatment with the small copy.
What do studies show about the time a substance stays in the body?
Researchers have not established a human half-life for TB-500, meaning the time an amount takes to fall by half. Researchers tested whole thymosin beta-4 during Phase 1, an early human safety study [6]. With larger amounts injected through a vein, more time passed before half the protein had cleared. That finding doesn't show how long your body retains the small copy.
Horse tests look for TB-500 and substances left as the copy breaks down, to detect banned use [12]. A detection test doesn't show how long the copy stays in a person. Other studies used rats' belly-space injections or Phase 1 injections through a vein [12]. Skin and eye experiments instead applied the larger protein directly to the area being treated.
Accounts of self-use describe muscle injections and injections just beneath the skin, while controlled human proof of benefit remains absent. Research products may contain unwanted material, uncertain ingredients, or a different protein piece from the one expected [12]. Uncertain contents make both harm and benefit harder for your doctor to judge. Human studies of the actual copy are needed to establish reliable timing for people.
Has research established a TB-500 half-life for human care?
A human half-life, the time an amount takes to fall by half, is not established for TB-500 [12]. In the Phase 1 vein study, clearing half the whole thymosin beta-4 amount took more time when larger amounts were given [6]. Tests detecting use in horses cannot answer how long your body retains the copy [12].